Asset sale Completed
Servier acquisition of Sevasemten and Edgewise muscular dystrophy business
US$1.6bn consideration
Announced 1 Jun 2026
Advisers
Sevasemten and Edgewise muscular dystrophy business
Target
- Financial adviser
- Legal adviser
Servier
Acquirer
Not disclosed
Other advisers
- Financial adviser
- Target
- Sevasemten and Edgewise muscular dystrophy business
- Acquirer
- Servier
- Seller
- Edgewise Therapeutics
- Target based in
- United States
- Buyer based in
- France
- Seller based in
- United States
- Completed
- 13 Jul 2026
- Sector
- Biotech
- Tags
- Biotech, Drug Development, Rare Disease
In the league tables
- M&A financial advisers, 2026 to date Centerview Partners #5 · Lazard #11
- M&A financial advisers, completed, 2026 to date Centerview Partners #7 · Lazard #14
- M&A legal advisers, 2026 to date Wilson Sonsini Goodrich & Rosati #22
- M&A legal advisers, completed, 2026 to date Wilson Sonsini Goodrich & Rosati #29
Similar deals
- Incyte acquisition of Vega Therapeutics Jun 2026 · US$1.3bn · Biotech
- Jazz Pharmaceuticals acquisition of Actio Biosciences Aug 2026 · US$820m · Biotech
- BioCryst Pharmaceuticals acquisition of Astria Therapeutics Oct 2025 · US$700m · Biotech
- Werewolf Therapeutics and Ambros Therapeutics merger Aug 2026 · US$500m · Biotech
- BioMarin Pharmaceutical acquisition of Alesta Therapeutics Aug 2026 · US$275m · Biotech
Sources
- 2026 Centerview Partners: Exclusive financial advisor to Edgewise on its sale of Sevasemten to Servier centerviewpartners.com
- 1 Jun 2026 Press release (EX-99.1, exhibit), Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on sec.gov
- 1 Jun 2026 Press release (PR Newswire), Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline prnewswire.com
- 13 Jul 2026 Press release (EX-99.1, exhibit), Edgewise Therapeutics Completes Sale of Sevasemten sec.gov
- 13 Jul 2026 Press release (PR Newswire), Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline prnewswire.com
- 13 Jul 2026 Lazard: FRANCE, UNITED STATES Servier to Acquire Edgewise Therapeutics’ Muscular Dystrophy Business lazard.com

